featured
Prophylactic Efficacy of Olanzapine-Based Therapy for Trastuzumab Deruxtecan–Associated Nausea and Vomiting in Patients With HER2-Positive or HER2-Low Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Annals of Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A randomized, double-blind, placebo-controlled phase II study of olanzapine based prophylactic antiemetic therapy for delayed and persistent nausea and vomiting in patients with HER2-positive or HER2-low breast cancer treated with trastuzumab deruxtecan: ERICA study (WJOG14320B)
Ann. Oncol 2024 Sep 05;[EPub Ahead of Print], H Sakai, J Tsurutani, Y Ozaki, H Ishiguro, K Nozawa, T Yamanaka, K Aogi, K Matsumoto, T Iwasa, M Tokiwa, M Tsuneizumi, Y Miyoshi, C Kitazawa, M Yamamoto, Y Takano, CK Imamura, Y Chiba, D Takiguchi, T Ezumi, T TakanoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.